Top Page
Grifols
(BME:GRF)
Grifols (GRF) vs. S&P 500 (SPY)
Grifols Business Overview & Revenue Model
Grifols Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 7.21B | 6.59B | 6.06B | 4.93B | 5.34B | Gross Profit |
| 2.85B | 2.49B | 2.23B | 1.96B | 2.26B | EBIT |
| 1.19B | 737.92M | 805.68M | 595.06M | 996.13M | EBITDA |
| 1.61B | 1.18B | 1.16B | 922.47M | 1.37B | Net Income Common Stockholders |
| 156.92M | 59.31M | 208.28M | 265.33M | 618.55M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.00B | 645.72M | 591.24M | 2.68B | 590.51M | Total Assets |
| 21.41B | 21.44B | 21.53B | 19.23B | 15.27B | Total Debt |
| 10.09B | 10.12B | 9.75B | 9.32B | 6.91B | Net Debt |
| 9.11B | 9.59B | 9.20B | 8.67B | 6.33B | Total Liabilities |
| 12.80B | 13.47B | 13.08B | 11.09B | 8.55B | Stockholders Equity |
| 5.88B | 5.83B | 6.13B | 6.10B | 5.11B |
| Cash Flow | Free Cash Flow | |||
| 669.63M | -87.14M | -386.43M | 281.89M | 747.78M | Operating Cash Flow |
| 902.17M | 208.28M | -10.87M | 596.98M | 1.11B | Investing Cash Flow |
| 886.67M | -397.64M | -1.98B | -29.39M | -858.12M | Financing Cash Flow |
| -1.36B | 186.04M | -173.49M | 1.47B | -354.40M |
Grifols Technical Analysis
Grifols Peers Comparison
Grifols Corporate Events
Grifols reported a strong financial performance in the first quarter of 2025, exceeding forecasts with a 7.4% increase in revenues and a 14.2% rise in adjusted EBITDA. The company’s strategic execution and robust demand in the Biopharma sector contributed to a 179% growth in net profit and improved free cash flow by 209 million euros. Despite a temporary dip in albumin sales due to license renewal in China, Grifols maintained a solid liquidity position and reduced its leverage ratio, positioning itself for sustained growth in 2025.
The most recent analyst rating on (ES:GRF) stock is a Buy with a EUR22.00 price target. To see the full list of analyst forecasts on Grifols stock, see the ES:GRF Stock Forecast page.
Grifols has announced that its subsidiary, Grifols Biotest Holdings GmbH, has received approval from the German Federal Financial Supervisory Authority for its public acquisition offer to delist Biotest AG. The offer aims to acquire all ordinary and non-voting preferred shares of Biotest not already held by Grifols, with the acceptance period running until June 6, 2025. This strategic move is expected to strengthen Grifols’ position in the biopharmaceutical industry and could have significant implications for shareholders and market dynamics.
Grifols, S.A. has announced its Ordinary General Shareholders’ Meeting scheduled for June 2025, where key agenda items include the examination and approval of financial statements, the appointment of Deloitte Auditores, S.L. for sustainability verification, and changes to the Board of Directors. The meeting will also address the approval of a new remuneration policy and a 2025 Share Incentive Plan, alongside authorizations for treasury share acquisitions and potential extraordinary meetings, reflecting the company’s ongoing efforts to enhance governance and shareholder engagement.
Brookfield Capital Partners (UK) Limited has clarified that there is no new information regarding potential transactions with Grifols S.A. despite recent media speculations. Brookfield is not in discussions with Grifols’ Board of Directors but continues to maintain a general dialogue with the company’s reference shareholders.
Grifols, S.A. has addressed recent media reports regarding potential acquisition talks with Brookfield Capital Partners, stating that its Board of Directors is unaware of any such discussions. This announcement clarifies the company’s current position and may impact investor perceptions and market speculation regarding Grifols’ future ownership and strategic direction.
Grifols has announced that its subsidiary, Grifols Biotest Holdings GmbH, will submit a public offer to purchase all ordinary and non-voting preferred shares of Biotest AG for delisting. This strategic move aims to enhance Grifols’ market position by integrating Biotest’s operations, with the offer subject to approval by the German Federal Financial Supervisory Authority.
Grifols has addressed a media report alleging ‘continuous fraud’ within its leadership, clarifying that the claims are unfounded. The company is currently undergoing an administrative sanctioning procedure initiated by the CNMV for potential inaccuracies in financial reports from 2021 to 2023. However, the CNMV has stated that these issues did not significantly affect Grifols’ accounting figures, and there is no evidence of fraud or economic benefit from the alleged irregularities.
Grifols reported record results for fiscal year 2024, with significant revenue growth and improved cash flow, driven by strong performance in its Biopharma division and strategic initiatives. The company achieved all planned innovation milestones, reduced leverage, and strengthened its balance sheet, positioning itself for sustainable growth beyond 2025.
Grifols has released its annual report on the remuneration of its directors, highlighting the company’s commitment to aligning its remuneration policy with shareholder interests and long-term sustainability. The report outlines the procedures and principles guiding director remuneration, emphasizing the need for market competitiveness and prudent risk management. The current policy, set to expire in 2025, aims to attract and retain talent while ensuring directors’ independence and adherence to regulatory standards.
Grifols has announced a significant change in its board leadership, with current Chairman Thomas Glanzmann stepping down after 19 years. Anne-Catherine Berner will succeed him as Non-Executive Chair, and the board will reduce its members from 13 to 12, eliminating the position of Lead Independent Director.